posted on 2021-06-28, 15:05authored byAnaïs Schaschkow, Lokman Pang, Valerie Vandenbempt, Bernat Elvira, Sara A. Litwak, Beata Vekeriotaite, Elisa Maillard, Marjorie Vermeersch, Flavia MM Paula, Michel Pinget, David Perez-Morga, Daniel J. Gough, Esteban N. Gurzov
Most obese and insulin-resistant individuals do
not develop diabetes. This is the
result of the capacity of β-cells to adapt
and produce enough insulin to cover the needs of the organism. The underlying mechanism of β-cell adaptation in obesity, however, remains
unclear. Previous studies have suggested a role for STAT3 in
mediating β-cell development and human glucose homeostasis, but little is known
about STAT3 in β-cells in obesity. We observed enhanced cytoplasmic expression
of STAT3 in severely obese and diabetic subjects. To
address the functional role of STAT3 in adult β-cells,
we generated mice with tamoxifen-inducible partial or full deletion of STAT3 in
β-cells and fed them a high-fat diet before analysis. Interestingly, β-cell
heterozygous and homozygous STAT3-deficient mice showed glucose
intolerance when fed a high-fat diet. Gene expression analysis by RNA-Seq
showed reduced expression of mitochondrial genes in STAT3 knocked down human
EndoC-βH1 cells and was
confirmed
in FACS-purified β-cells from obese STAT3-deficient mice. Moreover, silencing of
STAT3 impaired mitochondria activity in EndoC-βH1 cells and human islets,
suggesting a mechanism for STAT3-modulated β-cell function. We propose STAT3 as a regulator of β-cell
function, improving glucose-induced insulin
secretion in obesity.
Funding
This work was supported by a Fonds National de la Recherche Scientifique (FNRS)-MIS grant (33650793), European Research Council (ERC) Consolidator grant METAPTPs (GA817940) and a JDRF Career Development Award (CDA-2019-758-A-N).